Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.68 |
| ▸ | DRD2 | P14416 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | DRD4 | P21917 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1491170 | 0.93 | DRD2 (0.67) | HTR1ADRD2ALDH1A1PKMDRD3 | |
| SCHEMBL11080260 | 0.92 | HTR1A (0.67) | HTR1ADRD2ALDH1A1DRD3DRD4 | |
| SCHEMBL11029655 | 0.91 | HTR1A (0.68) | HTR1ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL11083772 | 0.91 | HTR1A (0.66) | HTR1ADRD2ALDH1A1DRD3 | |
| SCHEMBL11086815 | 0.91 | HTR1A (0.68) | HTR1ADRD2DRD3 | |
| SCHEMBL11630844 | 0.90 | HTR1A (0.67) | HTR1ADRD2ALDH1A1KMT2ADRD3 | |
| Hydrochloric Acid SCHEMBL11089984 | 0.90 | HTR1A (0.67) | HTR1ADRD2DRD3 | |
| Hydrochloric Acid SCHEMBL11082872 | 0.90 | HTR1A (0.67) | HTR1ADRD2DRD3 | |
| SCHEMBL3060824 | 0.88 | DRD2 (0.62) | HTR1ADRD2ALDH1A1PKMDRD3 | |
| SCHEMBL25408131 | 0.87 | PKM (0.65) | HTR1ADRD2ALDH1A1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183227-B1 | 1,2,4-TRIAZOLE DERIVATIVES AS SEROTONERGIC MODULATORS | PROSARIX LTD (GB) | 2014-09-24 | — | — | EP | disclosed |
| EP-2183227-B1 | 1,2,4-TRIAZOLE DERIVATIVES AS SEROTONERGIC MODULATORS | PROSARIX LTD (GB) | 2014-09-24 | — | — | EP | disclosed |
| US-8247420-B2 | Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-8222254-B2 | 1, 2, 4-triazole derivatives as serotonergic modulators | PROSARIX LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222254-B2 | 1, 2, 4-triazole derivatives as serotonergic modulators | PROSARIX LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-8222254-B2 | 1, 2, 4-triazole derivatives as serotonergic modulators | PROSARIX LIMITED (GB) | 2012-07-17 | — | — | US | disclosed |
| US-20100261732-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS SEROTONERGIC MODULATORS | PROSARIX LIMITED | 2010-10-14 | — | — | US | disclosed |
| US-20100261732-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS SEROTONERGIC MODULATORS | PROSARIX LIMITED | 2010-10-14 | — | — | US | disclosed |
| US-20100261732-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS SEROTONERGIC MODULATORS | PROSARIX LIMITED | 2010-10-14 | — | — | US | disclosed |
| EP-2183227-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS SEROTONERGIC MODULATORS | Prosarix Limited (GB) | 2010-05-12 | — | — | EP | disclosed |
| EP-2162135-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | Reviva Pharmaceuticals, Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2009019472-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS SEROTONERGIC MODULATORS | PROSARIX LIMITED (GB) | 2009-02-12 | — | — | WO | disclosed |
| WO-2009019472-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS SEROTONERGIC MODULATORS | PROSARIX LIMITED (GB) | 2009-02-12 | — | — | WO | disclosed |
| WO-2008144764-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING QUINOLINONE BASED ATYPICAL ANTIPSYCHOTIC AGENTS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | WO | disclosed |
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | REVIVA PHARMACEUTICALS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-6894052-B1 | Serotonergic receptor antagonist | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 2005-05-17 | — | — | US | disclosed |
| EP-1000046-B1 | PIPERAZINE DERIVATIVES ACTIVE ON THE LOWER URINARY TRACT | RECORDATI CHEM PHARM (CH) | 2003-11-26 | — | — | EP | disclosed |
| EP-1000046-A1 | PIPERAZINE DERIVATIVES ACTIVE ON THE LOWER URINARY TRACT | RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY (CH) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999006383-A1 | PIPERAZINE DERIVATIVES ACTIVE ON THE LOWER URINARY TRACT | RECORDATI S.A., CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1999-02-11 | — | — | WO | disclosed |
| US-4092416-A | Benzopyrone derivatives exhibiting anti-allergic activity | BOEHRINGER MANNHEIM GMBH (DT) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293736-A1 | Compositions, Synthesis, and Methods of Using Quinolinone Based Atypical Antipsychotic Agents | GRIN2D, GRIN2C, AP3D1 | HTR1A 77/4885DRD2 26/4885ALDH1A1 2027/4885 |
| US-20100261732-A1 | 1, 2, 4 -TRIAZOLE DERIVATIVES AS SEROTONERGIC MODULATORS | HTR1A, HTR5A, TPH1 | HTR1A 1/4885DRD2 76/4885ALDH1A1 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.